Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Five-year biochemical outcome after prostate brachytherapy for hormone-naive men <= 62 years of age
Autore:
Merrick, GS; Butler, WM; Lief, JH; Galbreath, RW;
Indirizzi:
Wheeling Hosp, Schiffler Canc Ctr, Wheeling, WV 26003 USA Wheeling Hosp Wheeling WV USA 26003 fler Canc Ctr, Wheeling, WV 26003 USA George Washington Univ, Med Ctr, Div Radiat Oncol & Biophys, Washington, DC 20037 USA George Washington Univ Washington DC USA 20037 , Washington, DC 20037 USA Wheeling Jesuit Univ, Wheeling, WV USA Wheeling Jesuit Univ Wheeling WV USA eling Jesuit Univ, Wheeling, WV USA
Titolo Testata:
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
fascicolo: 5, volume: 50, anno: 2001,
pagine: 1253 - 1257
SICI:
0360-3016(20010801)50:5<1253:FBOAPB>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
RADICAL RETROPUBIC PROSTATECTOMY; EXTERNAL-BEAM RADIATION; CANCER; ANTIGEN; CARCINOMA; RECURRENCE; THERAPY; RATES; IMPLANTATION; PATTERNS;
Keywords:
prostate cancer; brachytherapy; biochemical outcome; patient age;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Merrick, GS Wheeling Hosp, Schiffler Canc Ctr, 1 Med Pk, Wheeling, WV 26003 USA Wheeling Hosp 1 Med Pk Wheeling WV USA 26003 ing, WV 26003 USA
Citazione:
G.S. Merrick et al., "Five-year biochemical outcome after prostate brachytherapy for hormone-naive men <= 62 years of age", INT J RAD O, 50(5), 2001, pp. 1253-1257

Abstract

Purpose: To evaluate S-year biochemical disease-free outcome for hormone naive men 62 years of age or less who underwent transperineal ultrasound-guided permanent prostate brachytherapy. Methods and Materials: 76 patients underwent transperineal ultrasound guided prostate brachytherapy using either Pd-103 or I-125 clinical T1b-T2b NxM0 (1997 AJCC) adenocarcinoma of the prostate gland from April 1995 to October 1999. No patient was lost to follow-up, and no patient underwent pathologic lymph-node staging. 47 patients were implanted with either Pd-103 or I-125 monotherapy, and 29 patients received moderate-dose external-beam radiation therapy followed by a prostate brachytherapy boost. No patient received hormonal manipulation. The median patient age was 58 years (range, 48-62 years). The median follow-up was 37 months (range, 14-70 months). Follow-upwas calculated from the day of implantation. Biochemical disease-free survival was defined by the American Society of Therapeutic Radiation and Oncology (ASTRO) consensus definition. Results: The actuarial 5-year biochemical disease-free survival rate was 98.7%. For patients with low-, intermediate-, and high-risk disease, 97.7%, 100%, and 100%, respectively, were free of biochemical failure. The median posttreatment prostate-specific antigen (PSA) for the entire group was 0.2 ng/mL. When stratified by risk group, the median posttreatment PSA was 0.2,0.15, and 0.1 for patients with low-, intermediate-, and high-risk disease, respectively. Conclusion: With a median follow-up of 37 months, hormone naive patients less than or equal to 62 years of age hate a high probability of 5-year biochemical disease-free survival following permanent prostate brachytherapy with an apparent plateau on the PSA curve. (C) 2001 Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/09/20 alle ore 02:11:21